Relationships of diabetes and hyperglycaemia with intraocular pressure in a Japanese population: the JPHC-NEXT Eye Study

Hanyuda, Akiko; Sawada, Norie; Yuki, Kenya; Uchino, Makoto; Ozawa, Yoko; Sasaki, Mariko; Yamagishi, Kazumasa; Iso, Hiroyasu; Ohta, Michio; Tsugane, Shoichiro

doi:10.1038/s41598-020-62135-3

Cited by 19 publications

(13 citation statements)

References 57 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The results of this study are not in line with research conducted by (Baisakhiya et al, 2017); (Pimentel et al, 2015); (Hanyuda et al, 2020) and (Rizka et al, 2020), who stated in their research that there was a significant influence between blood sugar levels with increased IOP. The study noted that blood sugar levels affected IOP in both DM and non-DM patients.…”

Section: Discussioncontrasting

confidence: 98%

The success of glaucoma therapy in diabetes mellitus and non-diabetes mellitus

Meida¹,

Ikliluddin²,

Setyandriana³

et al. 2022

Qanun Medika

View full text Add to dashboard Cite

Glaucoma is a disease marked with damage to the optic nerve, chronic and can cause blindness. Glaucoma needs regular therapy to prevent blindness. This study was an observational study using a case-control approach. Data were analyzed using the Mann-Whitney test to determine the differences in blood sugar levels in the DM and non-DM groups and the Chi-Square test to determine differences in the success of glaucoma therapy in DM and non-DM patients. There were 66 samples of glaucoma patients in this study, consisting of 14 men (21.2%) and 52 women (78.8%). The mean age of the patients was 61.12 ± 9.17 years. The sample was divided into 2 groups, namely 34 DM patients (51.5%) and 32 non DM patients (48.5%). The Mann-Whitney test showed significant differences in blood sugar levels between the DM and non-DM groups (p <0.05). Blood sugar levels in the DM group were 202.59 ± 73.5 mg / dL and in the non-DM group was 106.19 ± 16.3 mg / dL. In conclusion, there is no difference in the success of glaucoma therapy in DM and non-DM patients. Keywords : glaucoma, glaucoma therapy, diabetes mellitusCorrespondence :nurshani_meida@yahoo.com

show abstract

Section: Discussioncontrasting

confidence: 98%

The success of glaucoma therapy in diabetes mellitus and non-diabetes mellitus

Meida¹,

Ikliluddin²,

Setyandriana³

et al. 2022

Qanun Medika

View full text Add to dashboard Cite

show abstract

“…Several antidiabetic compounds have shown potential for glaucoma treatment (Lin et al, 2015;Maleškić et al, 2017;Sterling et al, 2021) (Table 3). In support of this, several studies have suggested that diabetes mellitus is a risk factor for glaucoma (Oshitari et al, 2007;Chopra et al, 2008;Welinder et al, 2009;Zhou et al, 2014;Horwitz et al, 2016;Jung et al, 2018;Hanyuda et al, 2020). Thus, it raises the question of whether glaucoma may be associated with retinal insulin desensitization (Agostinone et al, 2018) as well as insulin desensitization of the brain as associated with Alzheimer's and Parkinson's disease (Faiq et al, 2014;Dada, 2017;Faiq and Dada, 2017).…”

Section: Glucagon-like Peptide 1 Agonists and Other Antidiabetic Agen...mentioning

confidence: 97%

Glucagon-Like Peptide 1 Receptor Agonists – Potential Game Changers in the Treatment of Glaucoma?

et al. 2022

View full text Add to dashboard Cite

Glaucoma is a common ocular neurodegenerative disease characterized by the progressive loss of retinal ganglion cells and their axons. It is the most common cause of irreversible blindness. With an increasing number of glaucoma patients and disease progression despite treatment, it is paramount to develop new and effective therapeutics. Emerging new candidates are the receptor agonists of the incretin hormone glucagon-like-peptide-1 (GLP-1), originally used for the treatment of diabetes. GLP-1 receptor (GLP-1R) agonists have shown neuroprotective effects in preclinical and clinical studies on neurodegenerative diseases in both the brain (e.g., Alzheimer’s disease, Parkinson’s disease, stroke and diabetic neuropathy) and the eye (e.g., diabetic retinopathy and AMD). However, there are currently very few studies investigating the protective effects of GLP-1R agonists in the treatment of specifically glaucoma. Based on a literature search on PubMed, the Cochrane Library, and ClinicalTrials.gov, this review aims to summarize current clinical literature on GLP-1 receptor agonists in the treatment of neurodegenerative diseases to elucidate their potential in future anti-glaucomatous treatment strategies.

show abstract

“…Storr-Paulsen et al 3 Schultz et al 37 Busted et al 15 Keoleian et al 38 Olsen et al 16 Inoue et al 39 Larsson et al 17 Sudhir et al 40 McNamara et al 14 Ziadi et al 41 Roszkowska et al 18 Sonmez et al 42 Rosenberg et al 19 Wiemer et al 43 Lee et al 20 Beato et al 47 Su et al 21 Wang et al 54 Oriowo et al 22 Xiao et al 55 Modis et al 23 Wang et al 57 Ozdamar et al 24 Calvo-Maroto et al 25 Briggs et al 26 Sanchis-Gimeno et al 27 Altay et al 30 Kumar et al 44 Jeziorny et al 45 Luo et al 46 Ramm et al 48 Çolak et al 49 Hanyuda et al 50 Taşlı et al 51 Srećković et al 52 Suraida et al 53 Deák et al 56 Kim and Kim 58 CCT, central corneal thickness.…”

Section: Increase In Cct Values No Increase In Cct Valuesmentioning

confidence: 99%

Effect of diabetes mellitus on quantitative corneal anatomy – A systemic review

Sanchis‐Gimeno

Hasrod

Calvo-Maroto

et al. 2022

Afr. vis. eye health

View full text Add to dashboard Cite

Background: Corneal changes occur as a direct consequence of diabetes mellitus (DM). The central corneal thickness (CCT) is a useful parameter that provides information about the status of the metabolism of the cornea and can therefore help monitor the progression of DM.Aim: The aim of this study was to determine the impact of DM on CCT and its correlation with diabetes duration and glycated haemoglobin (HbA1c) levels.Methods: The systematic review was undertaken to answer: (1) What effect does DM have on CCT values? (2) What effect does DM duration have on CCT values? (3) What effect does HbA1c levels have on CCT values? The Web of Science was used to conduct a computerised search for articles of CCT values in DM.Results: A total of 38 articles that met the criteria for inclusion were included in this systemic review. The researchers found 27 articles that observed increased CCT values in DM patients compared with control subjects. There were six studies in which increased CCT values were related to DM duration and 12 studies in which DM duration did not alter CCT values. Also, eight studies showed that CCT values increased with glycated haemoglobin levels, and 12 studies did not observe this.Conclusion: Diabetes mellitus patients usually present with increased CCT values although there is no unanimity about the effect of DM duration and increased HbA1c levels (poor glycaemic control) in the CCT values of DM patients.

show abstract

Relationships of diabetes and hyperglycaemia with intraocular pressure in a Japanese population: the JPHC-NEXT Eye Study

Cited by 19 publications

References 57 publications

The success of glaucoma therapy in diabetes mellitus and non-diabetes mellitus

The success of glaucoma therapy in diabetes mellitus and non-diabetes mellitus

Glucagon-Like Peptide 1 Receptor Agonists – Potential Game Changers in the Treatment of Glaucoma?

Effect of diabetes mellitus on quantitative corneal anatomy – A systemic review

Contact Info

Product

Resources

About